News/ US FDA approves Ironwood’s gout combination drug Richard Staines arthritis, AstraZeneca, FDA approvals 2017, gout, Ironwood Pharmaceuticals 0 Comment Good news for Ironwood, which forecast annual sales of up to $300m, despite black box kidney failure warning. Share X FDA approves Ironwood’s gout combination drug https://pharmaphorum.com/news/fda-approves-ironwoods-gout-combination-drug/
News/ UK & Europe Otezla gains NICE approval for psoriatic arthritis Marco Ricci arthritis, Celgene, NHS, NICE, Otezla 0 Comment Earlier decision to reject drug reversed. Share X Otezla gains NICE approval for psoriatic arthritis https://pharmaphorum.com/news/otezla-gains-nice-approval-psoriatic-arthritis/
News/ UK & Europe NICE says Otezla’s bargain price offsets lower efficacy Richard Staines arthritis, Celgene, cost-effectiveness, NICE, rheumatology 0 Comment Otezla cheap and convenient, but less effective than rivals, says NICE. Share X NICE says Otezla’s bargain price offsets lower efficacy https://pharmaphorum.com/transversal-categories/uk-and-europe/nice-backs-celgenes-arthritis-pill/
Clinical/ News Janssen’s RA candidate among hot topics at EULAR Richard Staines arthritis, biosimilar, EULAR, immunology, inflammation, Rheumatoid arthritis, rheumatology, UK 0 Comment But attendees warned to expect “oceanic” weather. Share X Janssen’s RA candidate among hot topics at EULAR https://pharmaphorum.com/news/janssens-ra-candidate-among-hot-topics-eular/